Scholarships are now open for the Nurses & Pharmacists HIV Clinical Forum 2020, London, 13 November. You can apply… https://t.co/XF8dX43BWj
Dr Michael Seah
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Emerging potential for an HIV cure
Dr Jintanat Ananworanich presented the first plenary session on the emerging potential for an HIV cure. She disussed how information gained from adult and infant studies showed that early treatment, rapid viral suppression and sustained seronegativity results in less reservoir seeding and an extended time to viral rebound following cessation of ART. This has important implications for targeting persistent virus, particularly replication competent virus.
Early attempts at a "shock and kill" strategy have been unsuccessful at significantly decreasing the amount of reservoir virus or killing affected cells. Fture strategies are likely to employ the use of multiple Latency Reversing Agents (LRA), the use of new classes of LRA and combination use with immune therapies. Trials in animal models using a TLR7 agonist with Ad26MVA vaccine demonstrated promise in animal models, with a reduced viral load in monkeys infected with SHIV following ART discontinuation.
Preliminary trials of VRC01, a broadly neutralising antibody (bNAb) has also shown to be ineffective. However, the more potent VRC07-523LS bNAb, combinations of bNAbs or combination with vaccines are more effective approaches being tried. A combination of VRC07+PGT121 (a vaccine) given to infant macaques 1-2 days after SHIV infection led to a complete clearance of the virus.
The final messages Dr Ananworanich presented were that new methodologies need to be considered in order to facilitate research, notably
- Consider parallel animal and human studies for combination therapies;
- Testing combinations with the same animal model;
- Streamlining the regulatory pathways for the use of agents for different indications; and
- Conducting psychosocial research concurrently with scientific studies